KR100831621B1 - The plant extracts composition for the blood glucose reducing action - Google Patents
The plant extracts composition for the blood glucose reducing action Download PDFInfo
- Publication number
- KR100831621B1 KR100831621B1 KR1020070101381A KR20070101381A KR100831621B1 KR 100831621 B1 KR100831621 B1 KR 100831621B1 KR 1020070101381 A KR1020070101381 A KR 1020070101381A KR 20070101381 A KR20070101381 A KR 20070101381A KR 100831621 B1 KR100831621 B1 KR 100831621B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- extract
- ginseng
- insulin
- Prior art date
Links
- 239000008280 blood Substances 0.000 title claims abstract description 91
- 210000004369 blood Anatomy 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 48
- 239000008103 glucose Substances 0.000 title abstract description 48
- 230000001603 reducing effect Effects 0.000 title abstract description 4
- 239000000419 plant extract Substances 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 56
- 235000000346 sugar Nutrition 0.000 claims abstract description 36
- 235000013305 food Nutrition 0.000 claims abstract description 32
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 29
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 29
- 235000008434 ginseng Nutrition 0.000 claims abstract description 29
- 230000002829 reductive effect Effects 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000001035 drying Methods 0.000 claims abstract description 16
- 238000001914 filtration Methods 0.000 claims abstract description 9
- 235000017276 Salvia Nutrition 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 8
- 239000012046 mixed solvent Substances 0.000 claims abstract description 5
- 241000208340 Araliaceae Species 0.000 claims abstract 6
- 240000007164 Salvia officinalis Species 0.000 claims abstract 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 241001061264 Astragalus Species 0.000 claims description 17
- 235000006533 astragalus Nutrition 0.000 claims description 17
- 210000004233 talus Anatomy 0.000 claims description 17
- 239000004615 ingredient Substances 0.000 claims description 13
- 244000241838 Lycium barbarum Species 0.000 claims description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 235000009508 confectionery Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 235000020710 ginseng extract Nutrition 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 235000002789 Panax ginseng Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 240000008415 Lactuca sativa Species 0.000 claims description 4
- 235000003228 Lactuca sativa Nutrition 0.000 claims description 4
- 235000015468 Lycium chinense Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 210000004209 hair Anatomy 0.000 claims description 3
- 240000006162 Chenopodium quinoa Species 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000183278 Nephelium litchi Species 0.000 claims description 2
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical compound O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 241000219098 Parthenocissus Species 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 235000007238 Secale cereale Nutrition 0.000 claims 1
- 235000021028 berry Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 11
- 230000003914 insulin secretion Effects 0.000 abstract description 8
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract description 8
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 244000302512 Momordica charantia Species 0.000 abstract description 5
- 235000009811 Momordica charantia Nutrition 0.000 abstract description 5
- 239000012676 herbal extract Substances 0.000 abstract description 5
- 240000000249 Morus alba Species 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 235000006760 Acer pensylvanicum Nutrition 0.000 abstract 2
- 241000219312 Chenopodium Species 0.000 abstract 2
- 241000319057 Kalopanax septemlobus Species 0.000 abstract 2
- 241000605445 Anemarrhena asphodeloides Species 0.000 abstract 1
- 240000006122 Chenopodium album Species 0.000 abstract 1
- 235000009344 Chenopodium album Nutrition 0.000 abstract 1
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract 1
- 241001106041 Lycium Species 0.000 abstract 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 84
- 206010012601 diabetes mellitus Diseases 0.000 description 58
- 102000004877 Insulin Human genes 0.000 description 43
- 108090001061 Insulin Proteins 0.000 description 43
- 229940125396 insulin Drugs 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 29
- 240000004371 Panax ginseng Species 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 23
- 230000001419 dependent effect Effects 0.000 description 18
- 239000002775 capsule Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 11
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 10
- 229960001052 streptozocin Drugs 0.000 description 10
- 240000001439 Opuntia Species 0.000 description 8
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 238000007410 oral glucose tolerance test Methods 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 6
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 6
- 229960003237 betaine Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 241001072909 Salvia Species 0.000 description 5
- -1 and in particular Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- 230000010030 glucose lowering effect Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 4
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 4
- 235000005493 rutin Nutrition 0.000 description 4
- 229960004555 rutoside Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000010902 straw Substances 0.000 description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 241000723267 Diospyros Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 244000305267 Quercus macrolepis Species 0.000 description 2
- 101100321409 Rattus norvegicus Zdhhc23 gene Proteins 0.000 description 2
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- FWCXELAAYFYCSR-XTOHQWFCSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,15S,16R,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-15,16-diol Chemical compound C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@H]([C@H](C[C@]5(C)[C@H]4CC[C@]23C)O)O)O[C@]11CC[C@H](C)CO1 FWCXELAAYFYCSR-XTOHQWFCSA-N 0.000 description 1
- VXIVYEDEIZTBBY-SVXWRWBYSA-N (3s,4r,5r)-1-amino-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound NC(O)C(=O)[C@@H](O)[C@H](O)[C@H](O)CO VXIVYEDEIZTBBY-SVXWRWBYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZNEIIZNXGCIAAL-UHFFFAOYSA-N 17alpha,20alpha-Dihydroxy-3,11-diketo-Delta4-pregnen Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CCC4CC5OC1OC(CO)C(O)C(O)C1O ZNEIIZNXGCIAAL-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- FWCXELAAYFYCSR-UHFFFAOYSA-N Episamogenin Natural products CC1C(C2(CCC3C4(C)CC(O)C(O)CC4CCC3C2C2)C)C2OC11CCC(C)CO1 FWCXELAAYFYCSR-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
- MMTWXUQMLQGAPC-YXOKLLKRSA-N Timosaponin A-III Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MMTWXUQMLQGAPC-YXOKLLKRSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SXKNCCSPZDCRFD-UHFFFAOYSA-N betaine aldehyde Chemical compound C[N+](C)(C)CC=O SXKNCCSPZDCRFD-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 239000009633 chimonin Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940043357 mangiferin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- MMTWXUQMLQGAPC-XWIAVXRASA-N timosaponin A-III Natural products C[C@@H]1CC[C@@]2(OC1)O[C@@H]3C[C@H]4[C@H]5CC[C@@H]6C[C@H](CC[C@]6(C)[C@H]5CC[C@]4(C)[C@@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O)[C@H]7O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O MMTWXUQMLQGAPC-XWIAVXRASA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 생약성분을 이용한 혈당강하용 식품 조성물에 관한 것으로, 상세하게는 여주, 명아주, 해동피, 인삼, 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 생약성분 추출물을 유효성분으로 함유하는 것을 특징으로 한다. 본 발명의 혈당강하용 식품 조성물은 당뇨병 환자의 혈당을 강하시키고 췌장 베타 세포의 파괴를 방지하는 동시에 손상된 베타 세포를 복원시켜 인슐린 분비를 증가시키는 작용을 하는 당뇨병 예방 및 치료 효과를 가지는 조성물로서 인슐린 의존형 당뇨병(제1형 당뇨병) 및 인슐린 비 의존형 당뇨병(제 2형 당뇨병)에 우수한 치료 효과를 나타낸다.The present invention relates to a food composition for lowering blood sugar using herbal ingredients, and in particular, extracts of herbal ingredients of Yeoju, Myeongju, Haedongpi, Ginseng, Zimor or Straw, Prickly Pear, White and White Peel, Gigolpi or Gugija, Salvia and Astragalus as active ingredients It is characterized by containing. The blood sugar-lowering food composition of the present invention is a composition having a diabetes prevention and treatment effect that lowers blood sugar of a diabetic patient and prevents destruction of pancreatic beta cells and at the same time restores damaged beta cells to increase insulin secretion. It exhibits excellent therapeutic effects on diabetes (
당뇨병 및 그의 합병증은 암, 신장순환기 질환과 더불어 전세계적으로 높은 사망률을 나타내는 질환으로 현재에도 사망률이 지속적으로 증가하고 있으며 발병시기도 이전 성인에서 발병하던 것이 점차적으로 소아시기부터 나타나는 현상을 보이고 있으며 당뇨 환자는 안 질환, 신장질환, 심장질환 등의 합병증에 걸릴 위험성이 높다는 보고도 있다.Diabetes and its complications, along with cancer and renal circulatory disease, are the leading causes of high mortality in the world. The mortality rate continues to increase. Patients have a high risk of developing complications such as eye disease, kidney disease and heart disease.
당뇨병의 증상은 다양하지만 대표적인 3대 증상으로 다음, 다뇨, 다식을 들 수가 있다. 즉 혈안 내에 높은 혈당치 때문에 소변으로 포도당 및 많은 양의 수분이 삼투압에 의하여 배설되게 되며 소변을 자주 보게 되고 따라서 탈수 증상으로 심한 갈증을 느껴 물을 많이 마시게 되며 또 공복감을 느껴 음식을 많이 먹게 되나 대체적으로는 체중이 많이 감소하는 현상을 나타내게 된다.Symptoms of diabetes vary, but the three major symptoms are Daum, multi urine, Dasik. In other words, due to high blood sugar levels in the blood, glucose and large amounts of water are excreted by osmotic pressure, and the urine is frequently seen. Therefore, dehydration causes severe thirst to drink a lot of water. As a result, a lot of weight is reduced.
당뇨병은 크게 인슐린 의존형 당뇨병(제1형)과 인슐린 비의존형 당뇨병(제2형)으로 분류한다. Diabetes is largely classified into insulin dependent diabetes mellitus (type 1) and insulin independent diabetes mellitus (type 2).
제1형인 인슐린 의존형은 당뇨병 성산 혈증(Diabetic Ketoacidosis)같은 위독한 증상이 발견되기도 한다. 미국과 유럽에서는 전체 당뇨병 환자의 약 5~10%가 제1형인 인슐린 의존형 당뇨 환자로 추정되나 우리나라에서는 약 1~2% 정도이다. Insulin-dependent,
제1형 인슐린 의존형 당뇨병의 원인으로 유전자인 HLA 항원(HLA, DR, DQ)과 연관성이 있으며 환경인자로서 바이러스 감염이나 기타 독성물질이 췌장의 인슐린 분비세포인 베타세포의 표면 항원으로 면역원을 변화시키며 이러한 자기 면역기전이 당뇨병의 발병에 관여하는 것으로 밝혀졌으며 소도세포 인슐린에 대한 자가 항체등이 생성된다. 최근 이러한 자가 항체 등을 제1형 당뇨병이 발생하기 전에 미리 검출하여 당뇨병의 발병을 늦추거나 예방하고자 하는 노력이 시도되고 있다.It is associated with HLA antigens (HLA, DR, DQ), a gene that causes
제2형인 인슐린 비 의존형 당뇨병은 주로 40대 이후에 발병되며 우리나라 당뇨병 환자의 대부분을 차지한다. 제 1형과 달리 성인형 당뇨병이라 불리며 발병 원인은 아직 명확히 밝혀지지 않았으나 유전적인 요인과 환경적인 요소가 함께 관여되어 발생되는 것으로 알려져 있다.Insulin-dependent diabetes mellitus, type 2, develops mainly after the forties and accounts for most of the diabetic patients in Korea. Unlike
유전인자로는 다양한 가족성 집중을 보이며 일란성 쌍생아 간에는 거의 90~100%에 달하는 질병 일치를 보이며 부모가 모두 당뇨병일 때에는 자식의 경우 58%, 부모 중 한 사람이 당뇨병일 경우 27%에서 부모가 모두 건강할 때에는 0.9% 정도 발병된다고 알려져 있다. 환경 인자로는 최근 경제 성장과 함께 급속히 증가하고 있는 고칼로리 섭취, 운동부족, 비만증, 스트레스 및 약물남용 등 많은 요인들이 당뇨병을 유발시키는 원인으로 작용하고 있다.Genetic factors include a variety of familial concentrations, with nearly 90-100% disease concordance between identical twins, 58% for children when both parents are diabetic, and 27% for parents when one of the parents is diabetic. It is known that about 0.9% of people are healthy. Environmental factors, such as high calorie intake, lack of exercise, obesity, stress and drug abuse, which are rapidly increasing with the recent economic growth, are causing the diabetes.
제 2 당뇨병의 병인으로 췌장 베타세포에서 인슐린 분비의 장애와 표적세포에서 인슐린 작용의 결함(인슐린 저항성)이 모두 관찰되는데 이중 어떠한 변화가 일차적 중요성을 갖는지는 아직 확실치 않다.The pathogenesis of diabetes mellitus is observed in both pancreatic beta cells and in insulin secretion and in target insulins (insulin resistance). It is not yet clear what changes are of primary importance.
당뇨병 치료 경우 혈당 강하제로는 설포닐-우레아 제제(Sulfonylureas), 비구아니드(Biguanides), 아카보스(Acarbose) 등이 있는데 이중 설포닐-우레아 제제는 작용시간이 짧고 혈당 강하 효과가 강한 제 2세대 제품이 주로 사용되며, 뚱뚱하지 않은 성인형 당뇨병 환자에게 비구아나이드(Biguanides)계 약물과 아카보스(Acarbose)는 정상 체중 이상의 비만인 당뇨병 환자에게 사용된다.In the treatment of diabetes, hypoglycemic agents include sulfonylureas, biguanides, and acarbose. Among them, sulfonyl-urea preparations are second generation products with short duration of action and strong hypoglycemic effects. It is mainly used, and in patients with obese adult diabetes, biguanides and acarbose are used for diabetics with normal weight or more.
또한 주사제 형태로 사용되고 있는 인슐린은 혈당강하 효과가 우수하나 사용 방법이 불편할 뿐 아니라 저 혈당이란 합병증을 일으키므로 주의가 필요하며, 특히 노인들에게는 이런 저혈당이 잘 일어나므로 적절한 주의가 필요하다.In addition, insulin used in the form of an injection is excellent in hypoglycemic effect, but not only inconvenient to use, but also low-glycemic complications that require attention, especially in the elderly, such hypoglycemia well occurs, so it is necessary to be careful.
이 같은 약물요법 이외에도 우리나라에서 행해지고 있는 민간요법은 총 158종으로 이중에 먹는 민간 요법류가 153종이나 되며 성인 당뇨병 환자의 약 73%가 한번 이상 민간 요법을 사용한 적이 있다는 보고가 있다.In addition to the drug therapy, there are a total of 158 folk remedies in Korea, and there are 153 folk remedies, and about 73% of adult diabetics have used folk remedies more than once.
당뇨병 치료 약물의 연구는 연구 및 치료 분야에 중점을 두어 연구되고 있는데 인슐린 의존형의 경우는 췌도염 방지 및 당뇨병 치료를 위한 연구가 MOD 마우스 등의 질환 모델 동물을 중심으로 이루어지고 있으며 대부분의 당뇨병 치료 전략은 베타 세포 파괴를 방지하기 위한 면역 반응억제 및 조절에 집중하고 있다. 자가 면역 질환인 인슐린 의존형 당뇨병(제1형 당뇨병)은 비정상적인 면역 기능의 증강에 기인하고 췌장의 베타 세포 파괴를 방지하기 위한 면역 치료법이 다양하게 시도되고 있다.The study of diabetes treatment drugs is focused on research and treatment fields. In the case of insulin-dependent cases, studies for preventing pancreatitis and treating diabetes are mainly conducted on disease model animals such as MOD mice and most diabetes treatment strategies. Focuses on suppressing and regulating immune responses to prevent beta cell destruction. Insulin-dependent diabetes mellitus (
신생아 흉선 제거법(Neonatal Thymectomy)은 T세포를 제거하여 NOD 마우스에서 당뇨 발병을 억제할 수 있다. 또한 T세포에 대한 항체를 처리하여 T세포를 제거하거나 대식 세포를 제거해도 당뇨 발병을 억제할 수 있음이 밝혀졌다. 면역세포에서 분비되는 NO등의 유리기(Free Radical)의 생성 및 작용 및 항산화제를 사용하여 당뇨를 억제할 수 있다는 보고가 있으며, 이에는 니코틴 아미드(Nicotinamide),비타민 E, 푸로부콜(Probucol) 등의 항산화제가 보고되었다.Neonatal Thymectomy can eliminate T cells to suppress the development of diabetes in NOD mice. In addition, it has been found that the treatment of antibodies to T cells removes T cells or macrophages to inhibit the onset of diabetes. It has been reported that the production and function of free radicals such as NO secreted from immune cells and anti-oxidants can be used to suppress diabetes, such as nicotinamide, vitamin E, probucol, etc. Antioxidants have been reported.
면역 억제제를 사용하는 치료법은 많은 연구가 이루어지고 있다. 그러나 클루코 코르티코이드(Glucocorticoid)나 시클로 포스파이드(Cyclophosphamide)를 이용한 당뇨병 치료는 유의한 효과를 나타내지 못하고 있으며 최근 시클로스포린 A(Cyclosporin A), 라파마이신(Rapamycin)을 이용한 당뇨병의 치료 가능성을 제시하고있지만 그 결과는 아직 확실하지 않다.Therapies using immunosuppressants are being studied. However, the treatment of diabetes with glucocorticoid or cyclophosphamide has no significant effect. Recently, it has suggested the possibility of treating diabetes with cyclosporin A and rapamycin. The result is not yet clear.
면역 억제제를 사용한 치료법은 과도한 면역 억제로 인해 2차 감염, 신장 독 성, 간 독성 등을 야기시켜 당뇨병 치료제로서의 사용에는 아직도 많은 문제점을 가지고 있고 또한 장기간 투여에 의한 치료시에는 암을 유발하는 경우도 있다.Treatment with immunosuppressive agents can cause secondary infections, kidney toxins, hepatotoxicity due to excessive immune suppression, and still have many problems for use as a therapeutic agent for diabetes. have.
최근 면역 억제제가 아닌 면역 조절제에 의한 당뇨병 예방 및 치료 연구가 진행되고 있으며 IL-4 및 IL-10등의 사이토가인 처리에 의해 NOD 마우스의 당뇨병이 억제됨이 보고되었다. 또한 인슐린 비 의존형은 부작용을 낮추고 인슐린 의존형 및 비 의존형 당뇨병을 동시에 치료할 수 있는 치료제를 개발하려는 노력이 이루어지고 있다. 민간 요법은 전통적으로 독성이 낮으면서 다양한 치료효과를 가지고 있다고 알려져 있다. 현재까지 수십 종의 생약제를 이용한 당뇨병 치료 효과가 보고되어 있으며 인슐린 의존형 및 비 의존형 당뇨병을 동시에 치료할 수 있다는 보고도 있다.Recently, studies on the prevention and treatment of diabetes mellitus by immunomodulators other than immunosuppressants have been conducted, and it has been reported that the cytokines such as IL-4 and IL-10 inhibit the diabetes of NOD mice. In addition, efforts are being made to develop a therapeutic agent that can lower insulin side effects and treat insulin dependent and non-dependent diabetes at the same time. Folk remedies have traditionally been known to have a variety of therapeutic effects with low toxicity. To date, the effects of diabetes treatment using dozens of herbal medicines have been reported, and there are reports that insulin-dependent and non-dependent diabetes can be treated simultaneously.
이에 본 발명자들은 부작용이 적은 생약제를 배합하여 인슐린 의존 및 비 의존형 당뇨형을 동시에 치료할 수 있는 조성물을 개발하기 위해 집중적인 연구를 수행하였으며, 10종의 생약성분 즉 여주, 명아주, 지모 또는 잔대, 해동피, 가시오기피, 상백피, 지골피 또는 구기자, 인삼, 단삼 및 황기의 생약성분 추출물을 함유하는 혈당강하용 식품 조성물이 베타세포의 인슐린 분비를 촉진시켜 인슐린 의존형 당뇨병을 치료할 수 있음과 식이 후 급격한 혈당 상승을 억제하여 말초 조직의 인슐린 저항성을 제거함으로서 인슐린 비 의존형 당뇨병을 치료할 수 있음을 동물실험을 수행한 결과 혈당 강하 작용과 개체별 치료 효과의 안정성이 우수함을 발견하고 본 발명을 완성하게 되었다.Therefore, the present inventors conducted intensive research to develop a composition capable of treating insulin-dependent and non-dependent diabetes mellitus at the same time by combining herbal medicines with fewer side effects, and 10 kinds of herbal ingredients, namely Yeoju, Myeongju, Jimi or Stirrup, and thawed skin. , Blood sugar lowering food composition containing medicinal herb extract of goji, baekbaekpi, phalanx or goji berry, ginseng, red ginseng and Astragalus can promote insulin secretion of beta-cells to treat insulin-dependent diabetes mellitus As a result of animal experiments showing that insulin-dependent diabetes mellitus can be treated by suppressing insulin resistance of peripheral tissues, the present inventors have found that the hypoglycemic action and the stability of individual treatment effects are excellent and the present invention has been completed.
따라서, 본 발명의 목적은 여주, 명아주, 해동피, 인삼, 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 생약성분 추출물을 유효성분으로 함유하는 혈당강하용 식품 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a hypoglycemic food composition containing herbal extracts of Yeoju, Myeongju, Haedongpi, Ginseng, Jimo or Straw, Prickly Pear, White and White Peel, or Gugija, Sweet Ginseng and Astragalus as active ingredients.
본 발명은 생약성분을 이용한 혈당강하용 식품 조성물에 관한 것으로, 상세하게는 여주, 명아주, 해동피, 인삼, 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 생약성분 추출물을 유효성분으로 함유하는 것을 특징으로 한다. 본 발명의 혈당강하용 식품 조성물은 인슐린 의존형 당뇨병(제1형 당뇨 병) 및 인슐린 비 의존형 당뇨병(제 2형 당뇨병)에 우수한 치료 효과를 나타낸다.The present invention relates to a food composition for lowering blood sugar using herbal ingredients, and in particular, extracts of herbal ingredients of Yeoju, Myeongju, Haedongpi, Ginseng, Zimor or Straw, Prickly Pear, White and White Peel, Gigolpi or Gugija, Salvia and Astragalus as active ingredients It is characterized by containing. The hypoglycemic food composition of the present invention exhibits an excellent therapeutic effect on insulin dependent diabetes mellitus (
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 혈당강하용 식품 조성물은 건조물 기준으로 여주 100 중량부에 대하여, 명아주 60 내지 350 중량부, 해동피 50 내지 225 중량부, 인삼 40 내지 200 중량부, 지모 또는 잔대 20 내지 175 중량부, 가시오가피 100 내지 426 중량부, 상백피 26 내지 175 중량부, 지골피 또는 구기자 20 내지 150 중량부, 단삼 20 내지 125 중량부 및 황기 50 내지 125 중량부로 이루어진 생약성분의 추출물을 포함한다. The blood sugar-lowering food composition of the present invention with respect to 100 parts by weight of dried liquor, 60 to 350 parts by weight, 50 to 225 parts by weight of thawed blood, 40 to 200 parts by weight of ginseng, 20 to 175 parts by weight of gimo or stalks,
상기에서 여주는 열매 뿐 만 아니라 씨도 포함된다.The above connotation includes not only the fruit but also the seed.
여주는 박과의 덩굴식물로 정식학명은 모모르디카 크란티아(Momordica Charantia)이다. 여주엔 비타민 C가 100그램중 120밀리그램이나 들어있는데 딸기의 80밀리그램, 레몬의 90밀리그램, 양배추의 40밀리그램 보다 많은 양을 포함하고 있다. 여주가 함유한 비타민 C 경우 열매를 가열하여도 거의 파괴되지 않는다. 또한 여주는 체내에서 비타민 A로 바뀌는 베타-케로틴과 칼륨, 철 등의 미네랄도 함유하고있으나 여주의 성분들 가운데서 특히 중요한 성분은 포도당 연소를 돕고 포도당이 체내에서 재합성되지 않게 하는 식물성 인슐린(P-Insulin)과 인슐린을 분비하는 췌장의 기능을 활발하게하는 지용성 성분인 카란틴(Charantin)이다. 식물성 인슐린의 경우 체내에서 인슐린과 유사한 작용을 하는데 펩타이드 일종으로 열매와 씨에 많이 함유되어있다. 또한 여주의 경우 인슐린 저항성을 개선하는데 많은 영향을 미 치는데 인슐린 저항성이란 인슐린은 충분히 분비되는데도 그 작용이 약해서 혈액속에 있는 당이 세포속으로 잘 유입되지 않는 상태를 말한다. 또한 여주는 베타-카로틴과 같은 항산화 성분이 많이 들어 있어 당뇨병의 합병증인 망막증이나 신증(심근경색, 뇌졸중 등의 혈관성 질환)에 대한 예방 효과도 기대할 수 있다.Litchi is a vine of a family of gourds and its official name is Mormordica Charantia. Yeoju contains 120 milligrams of vitamin C. It contains more than 80 milligrams of strawberries, 90 milligrams of lemon, and 40 milligrams of cabbage. Vitamin C, which is contained in bitter melon, is hardly destroyed by heating the fruit. Yeoju also contains minerals such as beta-carotene, potassium and iron, which are converted into vitamin A in the body, but a particularly important component of Yeoju is vegetable insulin (P-), which helps to burn glucose and prevent glucose from resynthesizing in the body. Insulin) and charantin, a fat-soluble component that activates the pancreas secreting insulin. Vegetable insulin acts similar to insulin in the body and is a kind of peptide, which is contained in fruits and seeds. In addition, Yeoju has many effects on improving insulin resistance. Insulin resistance refers to a condition in which insulin is weakly released but its action is weak, and sugar in the blood does not flow well into the cells. Yeoju is also rich in antioxidants such as beta-carotene, which can also be used to prevent retinopathy and nephropathy (vascular diseases such as myocardial infarction and stroke).
명아주는 쌍떡잎 식물 중심자목 명아주과의 한해살이 풀로 잎은 어긋나고 삼각상 달걀모양이며 어릴때 중심부에 붉은 빛이 들고 가장자리에 물결 모양의 톱니가 있다. 꽃은 양성이고 황록색이며 꽃잎은 없고 꽃받침은 5개로 갈라지며 5개의 수술과 1개의 암술이 있다. 열매는 꽃받침으로 싸인 포과이고 검은 종자가 들어있다. 명아주에 들어있는 성분으로는 로이신, 베타인, 트리고넬린 등의 아미노산, 지방산, 리놀산 등과 비타민 A, B, C를 함유하고 있다. 또한 소량의 크롬, 칼륨, 아연 등의 필수 미네랄을 함유하고 있다. 특히 크롬의 경우에는 동맥 경화를 방지하고 혈액중의 지방을 정상으로 유지하고 인슐린과 함께 당의 대사를 행한다. 또한 아연의 경우에는 췌장세포의 인슐린 형성을 돕는다.Ming-ju is a perennial plant of the dicotyledonous plant, the leaf is shifted, triangular egg-shaped, reddish at the center when it is young, and wavy at the edges. Flowers are bisexual, yellowish green, without petals, sepals divided into 5, with 5 stamens and 1 pistil. Fruits are poins wrapped in calyx, with black seeds. The components of Myeong-ju contains amino acids such as leucine, betaine, and trigonelin, fatty acids and linoleic acid, and vitamins A, B, and C. It also contains small amounts of essential minerals such as chromium, potassium and zinc. In particular, chromium prevents hardening of the arteries, keeps fat in the blood normal, and metabolizes sugar with insulin. Zinc also helps to form insulin in the pancreas.
해동피는 엄나무의 나무껍질을 말하는 것으로 주요성분은 Saponin, Flavonoids, Lignans, Phenols, Alkaloids, 아미노산 등이 있다. 엄나무는 주로 한국산, 일본산, 중국산으로 나누어진다. 잎은 호생하며 손바닥 모양으로 5~9 갈래로 갈라지며 밑이 심장형이고 열편은 난형으로 끝이 뾰쪽하고 날카로운 톱니가 있다. 해동피는 당뇨병의 치료작용 및 강장작용 그리고 신장의 기능을 튼튼하게 하는 효과를 가지고 있다.Haedongpi refers to the bark of the oak tree and its main components are Saponin, Flavonoids, Lignans, Phenols, Alkaloids, and amino acids. The oak tree is mainly divided into Korean, Japanese, and Chinese. Leaves are regenerated, palm-shaped, split into 5-9 branches, heart-shaped, lobe is ovate with sharp tip and sharp sawtooth. Haedongpi has the effects of treating and tonic and strengthen the kidney function of diabetes.
상백피는 뽕나무 뿌리껍질로서 특이한 냄새가 약간 나고 맛은 달고 성질은 차가운데 폐열로 인한 해수, 천식을 치료하며 이뇨 작용이 있다. 종합적인 약리작용은 진해, 이뇨, 혈압강하, 혈당강하, 진정, 진통, 해열, 진경, 항균작용 등을 나타내는데 특히 상백피에는 혈압을 낮추는 작용을 하는 구와논 성분이 많이 함유되어있어 혈관 내피세포에 작용하여 혈관확장을 유도시켜 콜레스트롤 감소효과를 유발시키며 이에 따른 이에 따른 부가적인 영향으로 혈당치를 낮추는 효과를 기대할 수 있다.Morus bark is a mulberry root bark that has a peculiar smell, tastes sweet, and is cold. It treats seawater and asthma caused by waste heat and has a diuretic effect. Comprehensive pharmacological action is Jinhae, diuretic, lowering blood pressure, lowering blood sugar, soothing, analgesic, fever, jingyeong, antibacterial effect, especially the epithelium contains a lot of guwanon component that lowers blood pressure acts on vascular endothelial cells By inducing vasodilation, inducing a cholesterol reduction effect, according to this additional effect can be expected to lower blood sugar levels.
지골피의 성분으로는 일반 및 무기성분 외에 베타인, 루틴, 구꼬아민 A, 베타시세트롤 등과 불포화 지방산 및 아미노산이 풍부하다. 무기성분에는 칼륨, 마그네슘, 칼슘, 철분, 아연이 함유되어있다. 베타인은 콜린이 산화되어 베타인 알데히드가 되고 이것이 다시 산화되면서 중요한 생리 기능을 가진 메틸기의 공급원인 베타인이 된다. 지골피의 베타인은 간장과 위장의 기능촉진, 동맥경화와 고혈압 예방, 근골강화와 빈혈 예방에 효과가 있다. 지골피에는 약 6~11mg/g 이 함유되어있다. 루틴은 최초로 메밀에서 분리되었으며 많은 양이 함유되어있다. 루틴의 주요 효능은 혈당과 콜레스테롤 저하효과가 강해 성인병 예방효과에 좋으며 루틴과 유사한 플라보노이드계 화합물은 지질대사 조절기능과 항산화 활성이 강하다. 구꼬아민 A 는 혈압을 강하하고 체온강하 작용과 해열 작용을 가지며 베타시토스테롤은 콜레스테롤의 흡수 억제 효과가 뛰어나 콜레스테롤 및 고지방에 의한 성인병 예방 효과를 가지고 있다. 또한 지골피는 식물성 불포화 지방산인 리놀렌산 및 리놀렐산 인 등이 많이 함유되어있고 체내 에너지 대사 과정중 효소적 반응에 의해 전환이 가능한 유기산은 신진대사를 촉진시키고 노화방지에도 효과가 있다.The component of the phalanges is rich in unsaturated fatty acids and amino acids such as betaine, rutin, gucoamine A, betacicetrol in addition to the general and inorganic components. Inorganic ingredients include potassium, magnesium, calcium, iron and zinc. Betaine oxidizes choline to betaine aldehyde, which in turn oxidizes to betaine, a source of methyl groups with important physiological functions. Betaine of the phalanges is effective in promoting the function of the liver and stomach, prevention of arteriosclerosis and hypertension, prevention of musculoskeletal strengthening and anemia. The phalanges contain about 6 ~ 11mg / g. Rutin was first isolated from buckwheat and contains high amounts. Rutin's main effect is to lower blood sugar and cholesterol, which is good for preventing geriatric diseases, and flavonoid compounds similar to rutin have strong lipid metabolism control and antioxidant activity. Gucoamine A lowers blood pressure, has a temperature-lowering effect and an antipyretic effect, and beta-cytosterol has an excellent effect of inhibiting the absorption of cholesterol and prevents adult diseases caused by cholesterol and high fat. In addition, the phalanges contain a lot of vegetable unsaturated fatty acids such as linolenic acid and linoleic acid phosphorus, and the organic acid which can be converted by enzymatic reaction during the body's energy metabolism process promotes metabolism and prevents aging.
지모는 나리과의 다년생 초본으로서 주요 성분으로는 Timosaponin A-1, Timosaponin a-III, Chimonin, Protcocathechic acid, pantothenic acid, Asphonin(C2H41013), Markogenin, Mangiferin, Sarsasapogenin, Nicotinic acid, 점액 및 탄닌질로 구성되어져 있다. 약리작용으로는 혈당량을 낮추고 용혈작용을 나타낸다.Jimo is a perennial herb of Liliumaceae, whose main components are Timosaponin A-1, Timosaponin a-III, Chimonin, Protcocathechic acid, pantothenic acid, Asphonin (C 2 H 41 0 13 ), Markogenin, Mangiferin, Sarsasapogenin, Nicotinic acid, mucus and Consists of tannins. Pharmacological action to lower blood sugar levels and hemolysis.
가시오가피는 오갈피 나무과에 속하는 낙엽성 관목인 가시오갈피나무의 줄기 껍질을 말린 것이다. 주성분은 트리테르페노이드계의 배당체 7종류인데 에레우테로사이드 A, B, C, D, E, F, G 이며 그 밖에 글루코오스, 갈락토오스 등의 당류 및 다당의 카로틴, 비타민 B1,B2,C,미네랄을 풍부하게 함유하고 있다. 또한 스테롤, 쿠마린, 리구닌, 플라본, 후타레인 등 배당체가 함유되어 있다. 스테롤은 성호르몬을 자극하는 작용이 있으며 쿠마린은 현저한 진정효과가 있다. 플라본에는 관상동맥을 확장하고 혈액의 양을 증가시키고 심근의 산소결핍에 견디는 능력을 높이는 작용이 있다. 이들의 많은 배당체가 뇌하수체를 자극하여 여러 기관의 능력을 높이며 호르몬의 분비를 활발하게 한다. 특히 엘레우테로 사이드 B1, 세사민, 이소프락시딘은 혈관확장, 혈압안정, 당뇨혈당치 개선 및 당뇨 합병증 예방에 영향을 미친다.Prickly Pear is a dried bark of the Prickly Pear, a deciduous shrub belonging to the Ogalpiaceae. Its main components are 7 types of glycosides of triterpenoids, which are ereuterosides A, B, C, D, E, F, and G. Other sugars such as glucose, galactose, carotene, vitamin B1, B2, C, Rich in minerals. It also contains glycosides such as sterols, coumarins, ligunin, flavones, and futarein. Sterols have the effect of stimulating sex hormones, and coumarin has a pronounced sedative effect. Flavones work to expand coronary arteries, increase blood volume and increase the ability of the myocardium to withstand oxygen deficiency. Many of these glycosides stimulate the pituitary gland to increase the ability of various organs and to stimulate hormone secretion. In particular, eleuteroside B1, sesamin and isoproxidine have an effect on vasodilation, blood pressure stabilization, diabetic blood sugar level and prevention of diabetic complications.
황기는 콩과에 속하는 다년생 초본인데 주성분은 포모노네틴, 베타인, 콜린, 이소쿠리티케닌 등의 성분이 함유되어있고 아미노산으로는 혈압강화 작용을 하는 가바와 항균작용을 하는 이소플라보노이드 성분 그리고 강장작용을 하는 사포닌 성 분이 들어있다. 황기는 이뇨작용, 강심작용, 강장보혈 작용, 혈관을 확장시켜 혈액순환을 좋게 하는 약리효과를 가지고 있다.Astragalus is a perennial herb belonging to legumes. Its main ingredients include pomononetin, betaine, choline, and isocuritikenin, and its amino acids include GABA, which acts to strengthen blood pressure, isoflavonoid, and tonic. Contains functional saponin components. Astragalus has a pharmacological effect that improves blood circulation by diuretic, cardiac, tonic blood, and blood vessel dilation.
잔대는 도라지과의 숙근초로 씨로 번식한다. 주성분은 뿌리에 사포닌과 이눌린이 있는데 약리작용은 고혈압, 강심작용, 항진균 작용을 한다.The stalk grows as a seed of the bellflower family. The main ingredient is saponin and inulin at the root, pharmacological action is hypertension, cardiac action, antifungal action.
단삼은 꾸풀과에 속하는 중국의 유명한 허브종의 한 가지로서 주성분은 클로로제닌산, 시나린, 루테오린, 카페오일퀸산, 시나로피크린, 아구에린, 그로세이민,시라소로사이드 이다. 강력한 항산화 활성에 따라 담즙 분비 활성 촉진기능 및 간세포 보호기능을 갖는 메카니즘을 가지고 있다. 약리 작용으로는 혈당조절, 간기능보호, 항산화 활성, 지방흡수억제, 관상동맥 질환예방 효과가 있다.Salvia is one of the well-known herbs in China belonging to the family of coupe, and its main ingredients are chlorogeninic acid, cinnaline, luteolin, caffeoyl quinic acid, cinnaropicrine, aguerrin, grosemine and sirasoloside. It has a mechanism that promotes bile secretion activity and hepatocyte protection according to strong antioxidant activity. Pharmacological effects include blood sugar control, liver function protection, antioxidant activity, fat absorption inhibition, and coronary artery disease prevention effect.
인삼의 주성분은 진세노사이드라고 명영한 30 여종의 사포닌이 분리되어있는데 구조적 특징에 따라 트리올계, 디올계, 올리나넨계로 나뉘어진다. 인삼에 존재하는 사포닌은 MG-Rb1, MG-Rc, MG-Rb1, MG-Rd 등이 있다. 인삼의 약리작용은 당뇨병 예방 및 치료에 있어서 인슐린의 분해억제 작용을 증강, 항지방 분해작용, 당뇨병 수반증상의 개선작용이 있다. 인삼에 함유된 트리올계 사포닌은 제1형 당뇨병 발생시기를 지연시키고 발생율을 감소시키며 췌장과 혈액중의 인슐린 함량도 증가시킬 뿐만 아니라 Pancreas 내로의 lymphocyte의 Infiltration도 억제한다. 특히 진세노사이드 Rb2는 뇨 알부민 배설을 억제하고 신장 중량 억제와 신사구체 비대를 억제한다. 추가적으로 인삼의 약리작용은 혈압 조절작용, 동맥경화 및 고지혈증 개선등 여러 가지 효과를 나타낸다.The main ingredient of ginseng is about 30 kinds of saponins, named Ginsenosides, which are divided into triols, diols, and olannanes. Saponins present in ginseng include MG-Rb1, MG-Rc, MG-Rb1, MG-Rd. The pharmacological action of ginseng has the effect of inhibiting the degradation of insulin in the prevention and treatment of diabetes, anti-fat decomposition, and improving the symptoms associated with diabetes. Triol-based saponins in ginseng delay the onset of
상기 생약성분의 추출물은 여주, 명아주, 해동피 및 인삼 각각에 대하여 탄 소수 1 내지 4의 저급알콜, 물 또는 이들의 혼합용매에서 환류시키거나 침적시킨 다음 여과한 후 25 내지 80℃에서 감압건조하여 수득된 분말상의 여주 추출물, 명아주 추출물, 해동피 추출물 및 인삼 추출물;과 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 혼합물을 탄소수 1 내지 4의 저급알콜, 물 또는 이들의 혼합용매에서 환류시키거나 침적시킨 다음 여과한 후 25 내지 80℃에서 감압건조하여 수득된 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 혼합물의 추출물;의 혼합추출물이다. 상기 얻어진 혼합추출물은 9%이하의 수분함량을 가지는 분말상인 것을 특징으로 한다.The extracts of the herbal components are obtained by refluxing or dipping in low alcohol, water or a mixed solvent of 1 to 4 carbon atoms, and then filtering and then drying under reduced pressure at 25 to 80 ° C for each of Yeoju, Myeongju, Haedongpi and Ginseng. Extracts of dried powdery extracts, Myeongju extract, Haedongpi extract and ginseng extract; and mixtures of balsam or stalks, thorns, vinegar, baekbaekpi, phalanges or wolfberry, sweet ginseng and Astragalus in reflux alcohols having 1 to 4 carbon atoms, water or mixed solvents thereof After extracting or immersed and filtered and dried under reduced pressure at 25-80 ° C., extracts of a mixture of hairs or stalks, prickly pears, baekbaekpi, phalanges or gojija, sweet ginseng and Astragalus are mixed extracts. The obtained mixed extract is characterized in that the powder having a water content of 9% or less.
상기 여주 추출물은 여주 분말을 에탄올에 투입하고 5~10일 침적시킨 후 25 내지 35℃에서 감압건조하여 수득되고; 명아주 추출물은 명아주를 물에 투입하고 가열하여 얻어진 추출액을 여과 및 25 내지 35℃에서 감압건조하여 수득되고; 해동피 추출물은 해동피 분말을 메탄올에 투입하고 환류시켜 얻어진 추출액을 여과 및 60내지 80℃에서 감압건조하여 수득되고; 인삼 추출물은 인삼 분말을 에탄올 및 물이 부피비 3~4:1로 혼합된 용매에 투입하고 환류시킨 다음 물 및 n-부탄올이 부피비 1:1~2로 혼합된 용매로 추출 및 여과하고 25 내지 60℃에서 감압건조하여 수득되고; 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 혼합물의 추출물은 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 혼합물을 물에 투입하고 가열하여 얻어진 추출액을 여과 및 70 내지 80℃에서 감압건조하여 수득되어진다.The extract of Yeoju is obtained by putting the Yeoju powder into ethanol and immersing for 5 to 10 days and drying under reduced pressure at 25 to 35 ° C; The extract of Myeongju wine is obtained by filtration and drying under reduced pressure at 25-35 ° C. the extract obtained by adding Myeongju into water and heating; The thawed skin extract was obtained by adding the thawed skin powder to methanol and refluxing the extract obtained by filtration and drying under reduced pressure at 60 to 80 캜; Ginseng extract is put ginseng powder into a solvent mixed with ethanol and water in a volume ratio of 3 to 4: 1 and refluxed, then extracted and filtered with a solvent mixed with water and n-butanol in a volume ratio of 1: 1 to 2 and 25 to 60 Obtained by drying under reduced pressure at 占 폚; Extracts of mixtures of hairy or stalks, thorny stalks, lettuce, skin, or goji berry, sweet ginseng and Astragalus are filtered and extracted by heating a mixture of hairs or stalks, thorny scabies, sangpipi, phalanx or Astragalus, sweet ginseng and Astragalus It is obtained by drying under reduced pressure at ~ 80 ℃.
또한, 상기 생약성분의 추출물의 수득 과정 중에서, 감압 건조 이전에 알콜과 물을 저온에서 감압휘발시켜 알콜성분이 완전히 휘발되어 제거된 수용액상의 생약성분 추출물을 분말상의 추출물 대신 사용할 수도 있다. 액상의 추출물을 사용하는 경우 제품 포장 후 살균 처리공정을 거친다. 상기 살균 처리공정으로 80~90℃에서 30분~1시간동안 중탕하는 방법과 오토 클레이버(Auto Claver)를 이용하여 100~110℃에서 30분~1시간동안 열처리 하는 방법을 이용한다.In addition, during the process of obtaining the extract of the herbal ingredient, the herbal ingredient extract in the aqueous solution in which the alcohol component is completely volatilized and removed by volatilizing the alcohol and water at low temperature before drying under reduced pressure may be used instead of the powdery extract. If liquid extracts are used, they are packaged and sterilized. As the sterilization process, a method of hot water at 80 to 90 ° C. for 30 minutes to 1 hour and a method of heat treatment at 100 to 110 ° C. for 30 minutes to 1 hour using an auto claver are used.
본 발명의 혈당강하용 식품 조성물에 유효성분으로 함유되는 분말상의 여주 추출물, 명아주 추출물, 해동피 추출물 및 인삼 추출물과 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 혼합물의 분말상의 추출물의 혼합추출물은 0호 캡슐에 총 0.4g의 혼합분말로 충진포장될 수 있다. Of powdery extracts of powdery woman's extract, mallow extract, ginseng extract and ginseng extract and the hairy or stalk, prickly pear, baekbaekpi, phalanx or gojija, sweet ginseng and Astragalus contained as an active ingredient in the blood glucose lowering food composition of the present invention The mixed extract may be packed and packed with a total powder of 0.4g in No. 0 capsules.
본 발명의 혈당강하용 식품 조성물은 혈당을 강하시키는 작용, 혈당의 상승 을 예방하는 작용 및 인슐린 분비를 증가시키는 작용을 하고, 인슐린 의존형(제1형 당뇨병), 인슐린 비의존형(제2형 당뇨병)에 탁월한 치료 효과를 나타내며, 개체간의 약효 발현 상태가 안정되어 치료 효과의 균등성이 나타나는 효과를 나타내어 점진적으로 늘어나는 당뇨 환자의 혈당 조절 및 당뇨 예방에 많은 도움을 주어 성인병 에방을 위한 국민 건강 증진에 많은 도움이 된다.The blood sugar-lowering food composition of the present invention acts to lower blood sugar, prevent the rise of blood sugar, and increase insulin secretion, insulin-dependent (
이하, 실시예에 의해 본 발명을 보다 구체적으로 설명하지만, 본 발명의 권리 범위가 이에 한정되는 것은 아니다. 당 업계에서 통상적으로 주지된 변형 수행될 수 있으며 이러한 변형도 본 발명의 권리 범위에 포함되는 것임을 밝혀둔다.Hereinafter, the present invention will be described in more detail with reference to Examples, but the scope of the present invention is not limited thereto. Modifications commonly known in the art may be made and it is understood that such modifications are included within the scope of the invention.
[실시예 1] 혈당강하용 식품 조성물의 제조Example 1 Preparation of a food composition for lowering blood sugar
건조분말 기준으로 여주 열매 및 씨의 분말 300g을 95% 에탄올 용액에서 6일 동안 총 3회에 걸쳐 추출한 후 상온에서 감압건조하여 여주 분말 15g을 수득하였다.On a dry powder basis, 300 g of the fruit and seed powders were extracted three times for six days in a 95% ethanol solution, and then dried under reduced pressure at room temperature to obtain 15 g of the powder.
건조물 기준으로 500 g의 명아주를 잘게 절단한 후 명아주 무게에 대하여 8배의 물을 가하고 3일동안 가열하여 얻어진 추출액을 70℃에서 감압건조한 다음 450℃ 오븐에 넣고 100시간동안 가열한 후 물로 추출하고 70℃에서 감압건조하여 명아주 분말 추출물 5g을 수득하였다.500 g of dried persimmons are chopped finely, 8 times water is added to the weight of the dried persimmons, and the extract is dried for 3 days. The extract is dried under reduced pressure at 70 ° C, put in an oven at 450 ° C, heated for 100 hours, and extracted with water. Drying under reduced pressure at 70 ° C. yielded 5 g of powder of Ming-Juiju.
건조물 기준으로 해동피 300 g를 1200g의 70% 메탄올에서 3시간동안 가열환 류, 600g의 70% 메탄올에서 2시간동안 가열환류, 600g의 70% 메탄올에서 2시간동안 가열환류시킨 다음, 총 3번의 가열로부터 얻어진 추출액을 합한 후 저온 감압 냉각 추출을 통해 메탄올을 휘발제거한 후 80℃에서 감압건조하여 해동피 분말 추출물 36g을 수득하였다.On a dry basis, 300 g of thawed skin was refluxed in 1200 g of 70% methanol for 3 hours, refluxed in 600 g of 70% methanol for 2 hours, and refluxed in 600 g of 70% methanol for 2 hours. The combined extracts obtained from the above were removed by volatilization of methanol through low temperature and reduced pressure cooling extraction, and then dried under reduced pressure at 80 ° C. 36 g were obtained.
건조 분말 기준으로 인삼 300g을 1200g의 75% 에탄올에서 4시간동안 가열환류, 600g의 75% 에탄올에서 2시간동안 가열환류, 600g의 75% 에탄올에서 2시간동안 가열환류시킨 다음, 총 3번의 가열로부터 얻어진 추출액을 합한 후 저온 감압 냉각 추출을 통해 에탄올을 휘발제거한 후 인삼추출물이 함유된 수용액에 n-부탄올 수용액(물:n-부탄올=1:2)를 가한 후 2회에 걸쳐 분리된 추출액은 60℃에서 감압건조하여 인삼 분말 추출물 48g을 수득하였다.On a dry powder basis, 300 g of ginseng was refluxed in 1200 g of 75% ethanol for 4 hours, refluxed in 600 g of 75% ethanol for 2 hours, and refluxed in 600 g of 75% ethanol for 2 hours. After the obtained extracts were combined, the ethanol was volatilized off by low temperature and reduced pressure cooling extraction, and then n-butanol aqueous solution (water: n-butanol = 1: 2) was added to the aqueous solution containing ginseng extract. Under reduced pressure at ℃ 48 g of ginseng powder extract was obtained.
건조물 기준으로 지모 200g, 가시오가피 600g, 상백피 200g, 구기자 200g, 단삼 150g 및 황기 150g을 혼합한 후 15000g의 물에 담궈 8시간동안 가열한 후 추출액을 추출한 후 80℃에서 감압건조하여 지모, 가시오가피, 상백피, 구기자, 단삼 및 황기의 혼합물의 분말 추출물 286g을 수득하였다.Based on the dry matter, 200g of gimpo, 600g of ginseng bark, 200g of lettuce, 200g of goji berry, 150g of red ginseng, 150g of red ginseng, 150g of soybean, and then immersed in 15000g of water, heated for 8 hours, extracted with extract and dried under reduced pressure at 80 ℃. 286 g of a powder extract of a mixture of Goji, Salvia, and Astragalus were obtained.
상기에서 수득된 여주 분말 추출물; 명아주 분말 추출물; 해동피 분말 추출물; 인삼 분말 추출물; 및 지모, 가시오가피, 상백피, 구기자, 단삼 및 황기의 혼합물의 분말 추출물;을 혼합한 후 60℃에서 감압건조시켜 수분함량이 8%가 되도록 건조한 다음, 혼합기로 균질하게 혼합하여 총 10가지의 생약성분의 분말 추출물을 390g 수득하였다.Yeoju powder extract obtained above; Quinoa powder extract; Thawed skin powder extract; Ginseng powder extract; And powdered extracts of a mixture of hairy, spiny skin, baekbaekpi, goji berry, red ginseng and Astragalus, and dried under reduced pressure at 60 ° C. to dry up to 8% water content, and then mixed homogeneously with a mixer for a total of 10 herbal ingredients 390 g of a powder extract of was obtained.
상기 총 10가지 생약 성분의 분말 추출물 혼합물 0.4g을 0호 캡슐에 충진포장하여 캡슐제로 제형화하였다.0.4 g of the powder extract mixture of the total ten herbal ingredients was packed into No. 0 capsules and formulated into capsules.
[실험예] Experimental Example
본 발명에 따른 혈당강하용 식품 조성물의 혈당 강하 효과를 알아보기 위하여 1차로 당뇨병 모델 마우스를 이용한 동물실험을 실시하고, 이후 인체에 대한 혈당 강하 효과를 실험 증명하였다.In order to examine the hypoglycemic effect of the hypoglycemic food composition according to the present invention, an animal experiment was first conducted using a diabetic model mouse, and then the experimental effects of hypoglycemic effect on the human body were demonstrated.
본 발명에 따른 혈당강하용 식품 조성물의 혈당 강하 효과를 알아보기 위한 동물 실험으로, ICR계 마우스에게 당부하실험(OGTT: Oral Glucose Tolerance Test)를 실시하였으며, 제 2형( 인슐린 비 의존형)당뇨병에 대한 치료 효과 규명을 위해 KK-AY 마우스에 대한 영향을 측정하였고, 제1형(인슐린 의존형) 당뇨병에 대한 효과를 규명을 위해 스트렙토 조토신 유발 당뇨병 마우스 및 NOD(non-obese diabetic) 마우스를 이용하여 실험하였다.As an animal experiment to investigate the hypoglycemic effect of the hypoglycemic food composition according to the present invention, an ICR mouse was subjected to an Oral Glucose Tolerance Test (OGTT), and to type 2 (non-insulin dependent) diabetes. The effects on KK-AY mice were measured to determine the therapeutic effect of the treatment, and streptozotocin-induced diabetic and non-obese diabetic (NOD) mice were used to investigate the effects on type 1 (insulin-dependent) diabetes. Experiment.
인체에 대한 혈당강하 효과는 인슐린 비의존형 당뇨환자를 대상으로 혈당강하 효과와 인슐린의 분비 등 개선정도를 측정하였으며, 또한 인슐린 의존형 당뇨환자에 대한 혈당강하 효과를 측정하였다.The hypoglycemic effect on the human body was measured by improving the hypoglycemic effect and insulin secretion in non-insulin dependent diabetic patients. Also, the hypoglycemic effect on the insulin-dependent diabetic patients was measured.
[실험예 1] 혈당 강하 정도 측정 - 동물실험Experimental Example 1 Measurement of Blood Glucose Dropping Level-Animal Experiment
본 발명에 따른 혈당강하용 식품 조성물의 혈당강하 효과를 규명하기 위해 SPF(Specific Pathogeus Free:특정병원 체 부재)상태의 5~6주령의 ICR계 마우스를 사용하여 당부하실험(OGTT)을 실시하여 실시예 1의 혈당강하용 식품 조성물과 대조군간의 혈당강하 효과를 비교확인하였다.In order to investigate the hypoglycemic effect of the hypoglycemic food composition according to the present invention, a glucose-loading test (OGTT) was conducted using 5-6 week old ICR mice in SPF (Specific Pathogeus Free). The hypoglycemic effect of the hypoglycemic food composition of Example 1 and the control group was compared and confirmed.
투여 용량은 성인 체중 60kg을 기준으로 선정하여 13.4mg/kg을 산출하였으며, MOUSE DOSE은 그의 10배량 134mg/kg으로 결정하여 수행하였다.The dose was calculated based on the weight of 60kg adult weight was calculated to 13.4mg / kg, MOUSE DOSE was carried out by determining its 10 times 134mg / kg.
실험방법으로는 실험동물 총 20마리를 설정하고 10마리씩 2개군으로 분류하고 24시간동안 절식시킨 후 실험군 1은 실시예 1의 캡슐제를 0.85% 식염수에 용해시킨후 초음파 처리하여 현탁액으로 조제한 후 매일 0.1ml씩 경구투여하고, 대조군 1은 0.85% 식염수 0.1ml씩 경구투여하였다.As a test method, a total of 20 experimental animals were set, divided into 2 groups of 10 animals, and fasted for 24 hours.
경구투여 1시간 경과 후 동일한 경로로 2g/kg의 D-(+)-Glucos를 10g 체중당 0.1ml씩 투여하였다. 혈당의 측정은 죤슨 앤죤슨사에서 제조한 혈당계를 이용하여 안구로부터 혈액을 매 0, 10, 30, 60, 120분에 채취하여 측정하여 그 결과를 하기 표 1 및 도 1에 나타내었다.After 1 hour of oral administration, 2 g / kg of D-(+)-Glucos was administered 0.1 ml per 10 g of body weight in the same route. Measurement of blood glucose was measured by collecting blood from the eye every 0, 10, 30, 60, 120 minutes using a blood glucose meter manufactured by Johnson & Johnson, and the results are shown in Table 1 and FIG. 1.
하기 표 1은 시료를 경구투여한지 30분 경과시 혈당을 측정하여 평균치화 표준편차를 나타낸 것이다.Table 1 below shows the mean standard deviation of blood glucose by 30 minutes after oral administration of the sample.
[표 1]TABLE 1
[실험예 2] KK-AY 마우스에 대한 혈당 강하 효과 실험[Experimental Example 2] Experiment of hypoglycemic effect on KK-AY mice
KK-AY마우스는 야생쥐에서 유래한 제2형 당뇨병 인슐린 저항성과 300~400mg/dl 의 혈당치를 보이는 동물이다. KK-AY 마우스에 대한 본 발명의 혈당강하용 식품 조성물의 치료효과를 확인하기 위해 KK-AY마우스를 이용하여 당부하실험(OGTT)을 실시하여 혈당 효과를 비교 확인하였다.KK-AY mice are type 2 diabetic insulin resistance derived from wild mice and have a blood glucose level of 300-400 mg / dl. In order to confirm the therapeutic effect of the blood glucose-lowering food composition of the present invention on KK-AY mice, a glucose-loading test (OGTT) was conducted using KK-AY mice to compare the blood glucose effects.
실험 방법으로는, KK-AY마우스 20마리를 10마리씩 2개군(실험군 2, 대조군 2)으로 나누고 실험군 2에는 실시예 1의 혈당강하용 식품 조성물을 0.85%식염수에 용해시켜 267mg/10ml/kg의 용량으로 매일 복강투여하고, 대조군 2에는 0.85%식염수를 10ml/kg의 용량으로 매일 복강투여하였다.In the experimental method, 20 KK-AY mice were divided into two groups of 10 mice (experimental group 2 and control group 2), and in experimental group 2, the blood glucose lowering food composition of Example 1 was dissolved in 0.85% saline to give 267mg / 10ml / kg. The dose was intraperitoneally administered daily, and in control 2, 0.85% saline was intraperitoneally administered at a dose of 10 ml / kg.
시료 투여후 8주동안 안와 정맥총에서 혈액을 채취하여 혈당을 측정하였으며[도 2], 시료를 투여하는 동안 KK-AY마우스의 체중을 측정[도 3]하여 본 발명의 혈당강하용 식품 조성물의 부작용을 관찰하였다.Blood glucose was measured by taking blood from the orbital vein for 8 weeks after the administration of the sample [FIG. 2], and the weight of KK-AY mice was measured during the administration of the sample [FIG. 3]. Was observed.
약물투여를 종료한 후 KK-AY마우스를 24시간 동안 절식시켰으며 대조군 2의 마우스에는 0.85%식염수를, 실험군 2의 마우스에는 실시예 1의 혈당강하용 식품 조 성물을 267mg/kg용량으로 복강투여하였다. 90분 후 글루코스를 1g/kg의 농도로 모든 마우스에 경구 투여하였다. 그 후 30, 45, 60, 90, 120분 후에 마우스의 안와 정맥총에서 혈액을 채취하여 혈당을 측정하였다.After the drug administration, KK-AY mice were fasted for 24 hours, and 0.85% saline was administered to the control group 2 mice and the blood glucose lowering food composition of Example 1 was administered to the mice in the experimental group at a dose of 267 mg / kg. It was. After 90 minutes glucose was administered orally to all mice at a concentration of 1 g / kg. After 30, 45, 60, 90, 120 minutes, blood was collected from the orbital vein of the mouse and blood glucose was measured.
KK-AY마우스에 대한 혈당변화 실험결과 도 2에 나타난 바와 같이, 대조군 2의 마우스의 경우 6주후부터 혈당이 상승하기 시작하여 평균 400mg/dl이상의 고혈당을 나타낸 반면, 실험군 2의 마우스는 평균 250mg/dl의 혈당을 보였다[도 2]. 또한, 대조군 2의 경우 글루코스 투여 30분 후 혈당이 200mg/dl 이상 증가하였다가 서서히 감소하는 반면, 실험군 2의 경우에는 글루코스 투여 후 동일한 시간대에 100mg/dl 정도의 혈당 증가를 보이고 그 후 급격히 감소하는 양상을 나타냈다.As shown in FIG. 2, the blood glucose level of the mice in the control group 2 increased after 6 weeks, and the average blood glucose level was over 400 mg / dl, whereas the mice in the experimental group 2 had an average of 250 mg / kg. dl showed blood glucose [FIG. 2]. In addition, in the control group 2, the blood glucose increased more than 200 mg / dl after 30 minutes of glucose administration and gradually decreased, whereas in the experimental group 2, the blood glucose increased about 100 mg / dl at the same time after glucose administration, and then rapidly decreased. It showed an aspect.
또한, 시료를 투여하는 8주 동안 KK-AY 마우스의 체중을 측정하여 본 시료의 부작용을 관찰한 결과 실험군 2의 마우스는 약물 투여에 의한 체중 감소를 나타내지 않았다[도 3].In addition, the body weight of KK-AY mice was measured for 8 weeks during the administration of the sample, and the side effects of the sample were observed. As a result, mice in the experimental group 2 did not show weight loss due to drug administration [FIG. 3].
[실험예 3] 스트렙토 조토신 유발 당뇨 마우스에 대한 실험Experimental Example 3 Experiments on Streptozotocin-induced Diabetic Mice
스트렙토 조토신(streptozotocin,STZ)은 D-글루코사민의 N-나이트로소 유도체로서 원래 항생제로 개발되었던 물질이다. 스트렙토 조토신은 세포내 NAD를 감소시키며, 이것이 베타세포를 파괴시켜 당뇨병을 유발하는 것으로 알려져 있다. 본 실험에서는 마우스에 60mg/kg의 스트렙토 조토신을 5일간 반복투여하여 인위적으로 제1형 당뇨병을 유발한 뒤, 시료를 투여하여 혈당의 변화를 비교 관찰하여 제1형(인슐린 의존형) 당뇨병에 대한 본 발명의 혈당강하용 식품 조성물의 치료 효과를 관찰하였다.Streptozotocin (STZ) is an N-nitroso derivative of D-glucosamine that was originally developed as an antibiotic. Streptozotocin reduces intracellular NAD, which is known to destroy beta cells and cause diabetes. In the present experiment, a 60 mg / kg streptozotocin was repeatedly administered to mice for 5 days to artificially induce
실험 동물은 대한실험동물센타로부터 공급 받아 청정실 내에서 온도 22℃,습도 55±5%, 조명 12L/12D의 조건하에서 관리하였다. 시험동물은 총 4개 군으로 나누었다.The experimental animals were supplied from the Korean Experimental Animal Center and managed in a clean room under the conditions of temperature 22 ° C, humidity 55 ± 5%, and illumination 12L / 12D. The test animals were divided into four groups.
대조군 3 : 스트렙토 조토신을 투여하지 않은 군Control group 3: group not administered streptozotocin
대조군 4 : 스트렙토 조토신 60mg/kg을 35회 복강투여한 군Control group 4: group intraperitoneally administered
대조군 5 :스트렙토 조토신 60mg/kg과 위약으로 0.85% saline액 10 ml/Kg을 투여한 군Control group 5: group treated with
실험군 3 : 스트렙토 조토신 60mg/kg과 위약으로 0.85% saline액 10ml/Kg 및 실시예 1의 혈당강하용 식품 조성물 267mg/ml/kg을 투여한 군Experimental Group 3: Groups administered with streptozotocin 60mg / kg and placebo 10ml / Kg 0.85% saline solution and the blood sugar lowering food composition of Example 1 267mg / ml / kg
약물투여는 투여당일부터 23일간 투여하였으며, 매 4일마다 혈당, 요당 및 체중을 측정하였다.Drug administration was administered for 23 days from the day of administration, blood glucose, urine glucose and body weight were measured every 4 days.
상기 대조군 3, 대조군 4, 대조군 5 및 실험군 2의 개체별 혈당측정 결과를 하기 표 2에 나타내었으며, 측정 기술상 최고 혈중농도 500mg/dl까지만 측정하였다. 약물 투여 8일째의 각 군별 평균 혈당치를 비교하여 도 4에 도식화하였고, 약물투여 전/후 총 8일간의 각 군별 혈당 평균치의 변화를 그래프로 도 5에 나타내었다.The blood glucose measurement results of each of the control group 3,
도 4 및 도 5에 나타낸 바와 같이, 혈당치 300mg/dl 이상을 당뇨 마우스로 판정할 때 대조군 4에서는 시험을 마친 마우스 10마리 중 9마리, 대조군 5에서는 10마리 중 8마리가 당뇨로 판정받았다. 이에 비해 치료를 실시한 실험군 3에서는 10마리 중 2마리의 경우에만 발증을 보였다.As shown in FIG. 4 and FIG. 5, when a blood glucose level of 300 mg / dl or more was determined to be a diabetic mouse, 9 out of 10 mice tested in the
이상의 실험을 통해서 시료를 투여한 실험군 3에서 본 발명의 혈당강하용 식품 조성물을 투여시킴으로써 STZ마우스의 당뇨병 발병이 억제되었음을 알 수 있었다.Through the above experiments, it was found that the incidence of diabetes mellitus of STZ mice was suppressed by administering the blood glucose lowering food composition of the present invention in the experimental group 3 to which the sample was administered.
[표 2] STZ 마우스의 개체별 혈당측정치[Table 2] Blood glucose measurement by individual of STZ mouse
[실험예 4] 제2형(인슐린 비의존형) 당뇨환자 임상 실험Experimental Example 4 Clinical Experiment of Type 2 (Insulin-Independent) Diabetic Patients
인슐린 비의존형(NIDD)당뇨병 환자에 대한 본 발명의 혈당강하용 식품 조성물의 혈당강하 효과를 검증하기 위해 총 23명의 NIDD환자를 대상으로 경구 포도당 부하실험(Oral Glucose Tolerance Test)을 실시하였다. 실험기간은 2006년 1 월~2006년 9월까지 실험기관은 미국 오레곤주 포틀랜드에 위치한 ILDO한의원에서 실험 기간중 내원치료를 받은 인슐린 비의존형 환자중 60일 이상 계속하여 치료를 받은 23명의 환자이며, 실험약은 본 발명에 따른 혈당강하 식품 조성물을 사용하였다.In order to verify the hypoglycemic effect of the hypoglycemic food composition of the present invention on insulin-independent (NIDD) diabetic patients, oral glucose loading test (Oral Glucose Tolerance Test) was performed on 23 NIDD patients. From January 2006 to September 2006, the laboratory consisted of 23 patients who were treated continuously for more than 60 days of non-insulin dependent patients who were treated at the ILDO Oriental Medical Center in Portland, Oregon, USA. The test drug used the hypoglycemic food composition according to the present invention.
먼저 실험을 위한 실험자 선정을 크게 세가지로 나누어 선정하였다.First, the experimenter selection for the experiment was largely divided into three.
선정 실험자는정맥혈당의 측정결과 ① 공복시 혈당이 7.8 mmol/L (140mg/dl)이상이거나, 식후 혈당이 11.1mmol/L (200mg/dl)이상인 자, ② 공복시 혈당이 7.8mol/L (140mg/dl) 이하라도 경구 포도당 부하실험의 결과 혈당이 11.1 mmol/L (200mg/dl) 이상인 자 및 ③ OGTT 1시간 후의 혈당 및 2시간 후의 혈당이 11.1 mmol/L (200mg/dl) 이상인 자를 선택하였고, 위 선정 기준에 부합되는 사람들 중 아래의 경우에 해당되는 자는 제외하였다.The results of the measurement of venous blood glucose were: ① Fasting blood sugar of 7.8 mmol / L (140 mg / dl) or higher, and post-prandial blood sugar of 11.1 mmol / L (200 mg / dl) or higher. ② Fasting blood sugar of 7.8 mol / L (140 mg / L) dl), or less than 11.1 mmol / L (200mg / dl) blood glucose, and 3 or more blood glucose after 1 hour OGTT and 11.1 mmol / L (200 mg / dl) after 2 hours were selected as a result of oral glucose loading test, Those who meet the above selection criteria are excluded from the following cases.
실험약 투약전의 혈당은 상기 조건에 해당되더라도 운동요법이나 식이요법을통해 공복 혈당이 7.8mmol/L (140mg/dl) 이하이거나, 2시간 후의 혈당이 11.1 mmol/L (200mg/dl) 이하인 자, 실험규정을 위반하여 결과 산출에 영향을 초래하는 자, 제1형(인슐린의존형) 환자로 판명된 자, 실험 1개월 내에 당뇨병 성 케토시스나 아시도시스 환자로 판정된 자, 심각한 합병증이 있는 자, 정신질환자, 치료중단자, 15세 이하 또는 임산부나 산모 등Blood sugar before administration of experimental drugs is below 7.8mmol / L (140mg / dl) of fasting blood sugar or less than 11.1mmol / L (200mg / dl) of blood sugar after 2 hours through exercise or diet, Those who violate the experimental regulations and influence the outcome calculation, proved to be type 1 (insulin-dependent) patients, diagnosed as diabetic ketosis or asysis patients within one month of the experiment, had serious complications, and mental illness , Treatment interruption, under 15 years old or pregnant or mother
<관찰방법>Observation Method
공복 및 식사 2시간 후의 혈당을 측정한 후, 경구 포도당 부하시험(Oral Glucose Tolerance Test), 인슐린 분비능시험(Insulin Release Test), 혈중 Amino-fructose의 측정을 실시하였다.After the blood glucose was measured 2 hours after an empty stomach and a meal, oral glucose load test (Oral Glucose Tolerance Test), insulin release test (Insulin Release Test), blood Amino-fructose was measured.
위 측정 중 [공복 및 식사 2시간 후의 혈당 측정]은 필수 항목이고 이외의 항목 필요시마다 측정한다. 이후 투약 60일 후 실험 전 측정치와 비교하였다.[Measuring glucose level after 2 hours on an empty stomach and a meal] of the above measurement is an essential item, and it measures every other item as needed. It was then compared with the
<투약방법><Dose Method>
실험약을 1일 3회, 1회 800mg(2캡슐)을 식사 30분전에 물 등의 음료와 함께 경구투여하였다.800 mg (2 capsules) of the test drug three times a day, orally administered with a drink, such as
실험 대상자 총 23명의 인슐린 비의존형 당뇨환자 중 ,현저한 효과를 나타내는 분류 중 투약후 공복시 혈당이 7.2mmol/L (130mg/dl)이하이거나 식후 2시간 후의 혈당이 8.3 mmol/L (150mg/dl) 이하인 경우가 17명(73.9%)이고, 유효한 경우인 투약후 공복시 혈당이 8.3 mmol/L (150mg/dl)이하이거나 식후 2시간 후의 혈당이 10 mmol/L (180mg/dl) 이하인 경우가 5명(21.7%)이 해당되었다. 무효한 경우는(치료 후 증상의 개선이 없는자) 1명(4.4%)뿐이었다.Among 23 insulin-independent diabetic subjects, fasting blood glucose level was 7.2 mmol / L (130 mg / dl) or less than 8.3 mmol / L (150 mg / dl) at 2 hours after eating. Seventeen patients (73.9%) had an effective fasting blood glucose level of 8.3 mmol / L (150 mg / dl) or less than 10 mmol / L (180 mg / dl) after 2 hours. 21.7%). Only one patient (4.4%) had no improvement after treatment.
상기 평균 혈당 강하 경과기간은 26.7일 소요되었으며, 특이한 부작용은 관찰되지 않았고, 일부 환자에게서 시험 기간중 복부팽만, 설사 등이 관찰되었으나, 투약시기를 조절한 후 증상이 호전되어 투약을 계속하였다.The average period of hypoglycemia was 26.7 days, and no adverse side effects were observed. Some patients observed abdominal distension and diarrhea during the trial period, but after adjusting the administration time, symptoms improved and continued the administration.
이상의 실험을 통해 본 발명에 따른 혈당강하용 식품 조성물을 시험약으로 투여한 인슐린 비 의존형 당뇨환자에 대하여 경구용 혈당 강하제나 이미 알려진 생약 추출물에 비하여 우수한 혈당 강하 작용을 나타내며 독성이나 부작용 관련하여 안전한 것으로 확인되었다. Through the above experiments, the insulin-dependent diabetic patients who administered the hypoglycemic food composition according to the present invention as a test drug showed an excellent hypoglycemic action compared to oral hypoglycemic agents or known herbal extracts and were safe in terms of toxicity and side effects. Confirmed.
[실험예 5] 제1형(인슐린 의존형) 당뇨환자 임상 실험 1Experimental Example 5
포틀랜드 거주 46세의 남성으로 2004년 삼다 현상과 2개월만에 95kg에서 74kg으로 급격한 체중감소를 보이며 제1형 당뇨병 진단을 받았으며, 2004년 급격한 혈당상승(공복시 280mg/dl)과 시력감퇴 등의 합병증으로 40일간 입원치료받고 퇴원 후 인슐린을 1일 35단위씩 투여하였다. 인슐린 투여기간 중 혈당은 280~300mg/dl로 유지된 상태이다.A 46-year-old man living in Portland, South Korea, was diagnosed with
2006년 1월 환자본인 및 보호자의 동의를 구하고 본 발명에 따른 혈당강하용 식품 조성물의 캡슐제(실시예 1)를 실험약으로 1회 2캡슐씩, 1일 3회, 식전 30분에 복용토록 하였다. 5일간 복용후 혈당이 138mg/dl로 개선되어 인슐린 투여량을 15단위로 감소하였고, 1주일 후 다시 혈당 측정결과 140mg/dl로 확인되어 다시 5단위를 감소시켰으며, 같은 방법으로 복용 후 6주만에 인슐린 공급을 중단하였다. 이 후 공복시 혈당이 140~180mg/dl의 상태가 유지되어 복용량을 매 1캡슐씩 감소시킨 결과, 2006년 3월 1일 3캡슐로 정상혈당을 유지하고 있으며, 시력저하나 합병증은 함께 개선되었다. In January 2006, patient's and guardian's consent was obtained and capsules (Example 1) of hypoglycemic food composition according to the present invention were taken as an experimental drug, two capsules once a day, three times a day, 30 minutes before meals. It was. After taking 5 days, blood glucose improved to 138mg / dl, reducing insulin dose to 15 units, and after 1 week, the blood glucose was found to be 140mg / dl again, and then decreased to 5 units again. The insulin supply was stopped. After fasting blood glucose levels of 140-180 mg / dl, the dose was reduced by 1 capsule. As a result, 3 capsules were maintained on March 1, 2006 to maintain normal blood sugar, and visual acuity and complications improved.
[실험예 5] 제1형(인슐린 의존형) 당뇨환자 임상 실험 2Experimental Example 5 Clinical Experiment 2 of Type 1 (Insulin-Dependent) Diabetes Patients
직장인으로 2000년 7, 8월부터 삼다현상과 함께 81kg에서 67kg으로 체중이 급격하게 감소하여 진단결과 제1형(인슐린 의존형)당뇨병으로 판정, 공복시 혈당이 240~280mg/dl까지 측정되었으며 이후 1주일간 입원하여 인슐린 부하 실험 등을 거쳐 1일 2회 35단위씩 인슐린을 투약하였으나 계속적인 인슐린 공급에도 불구하고 혈당치는 220~270mg/dl로 특별히 개선되지 않았다. 특히, 인슐린 투여 후 혈압의 강하 등 부작용이 발생하고 있었다.As a worker, he lost weight rapidly from 81kg to 67kg with Samda phenomena from July to August 2000. The diagnosis resulted in type 1 (insulin-dependent) diabetes, and fasting blood sugar was measured to 240-280mg / dl. Insulin was administered 35 units twice a day through an insulin load test, but blood glucose levels did not improve to 220-270 mg / dl despite continuous insulin supply. In particular, side effects such as a drop in blood pressure occurred after administration of insulin.
투약 및 결과로는 2006년 4월 환자 본인 및 보호자의 동의를 구하고 본 발명에 따른 혈당강하용 식품 조성물의 캡슐제(실시예 1)를 실험약으로 1회 2캡슐씩, 1일 3회, 식전 30분에 복용토록 지도하였으며, 인슐린의 공급을 중단하는 대신 매일 1회 혈당치를 검사하였다. 처음 5주간은 혈당치의 변화가 없었으나, 6주부터 혈당이 강하하기 시작하여 7주째 180mg/dl 이하로 떨어졌으며, 8주째부터 1일 3 캡슐 복용 공복시 혈당이 120~169mg/dl로 유지되고 있으며, 삼다 현상의 소실과 함께 체중이 82kg으로 증가하였다.As a result of administration and results, in April 2006, the patient and his / her guardian agreed, and the capsule (Example 1) of the hypoglycemic food composition according to the present invention was used as an experimental drug twice a capsule, three times a day, before meals They were instructed to take it at 30 minutes, and the blood glucose level was checked once daily instead of stopping the supply of insulin. In the first 5 weeks, blood glucose levels did not change, but blood sugar began to drop from 6 weeks and dropped to 180 mg / dl at 7 weeks, and fasting blood glucose was maintained at 120 to 169 mg / dl from 3 capsules per day from 8 weeks. In addition, the body weight increased to 82 kg with the loss of phenomena.
상기 실험 결과로부터, 본 발명에 따른 여주, 명아주, 해동피, 인삼, 지모 또는 잔대, 가시오가피, 상백피, 지골피 또는 구기자, 단삼 및 황기의 생약성분 추출물을 함유하는 혈당강하용 식품 조성물은 동물 실험과 임상실험을 통하여 인슐린 의존형(제1형 당뇨병)과 인슐린 비의존형(제2형 당뇨병)환자의 혈당강하에 매우 유용한 식품 조성물임을 알 수 있었다.From the above experimental results, blood sugar lowering food composition containing herbal extracts of Yeoju, Myeongju, Haedongpi, Ginseng, Zimor or Straw, Prickly Pear, Gojipi, Gigolpi or Gugija, Salvia and Astragalus according to the present invention, animal experiment and clinical experiment It can be seen that it is a very useful food composition for lowering blood glucose levels of insulin-dependent (
도 1 - 실험예 1의 ICR 마우스의 OGTT 실험1-OGTT experiment of the ICR mouse of Experimental Example 1
도 2 - 실험예 2의 KK-AY 마우스의 혈당 변화2-Blood glucose change of KK-AY mice of Experimental Example 2
도 3 - 실험예 2의 KK-AY 마우스의 체중 변화3-Weight change of KK-AY mice of Experimental Example 2
도 4 - 실험예 3의 8일차 평균 혈당치Figure 4-
도 5 - 실험예 3의 혈당강화 효과 STZ 실험5-STZ experiment of glycemic effect of Experiment 3
Claims (5)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20070075020 | 2007-07-26 | ||
| KR1020070075020 | 2007-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR100831621B1 true KR100831621B1 (en) | 2008-05-27 |
Family
ID=39664964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020070101381A KR100831621B1 (en) | 2007-07-26 | 2007-10-09 | The plant extracts composition for the blood glucose reducing action |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100831621B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101130635B1 (en) | 2009-07-01 | 2012-04-09 | 주두권 | The manufacturing process of momordica charantia tea |
| CN102551061A (en) * | 2012-02-10 | 2012-07-11 | 福州市鼓楼区大特生物技术有限公司 | Canarium album granule with hypolipidemic and hypoglycemic effects and preparation process of same |
| KR101289084B1 (en) | 2011-12-08 | 2013-07-30 | 윤병재 | The tea containing natural medicinal herbs and the manufacturing method of it |
| KR101312491B1 (en) | 2012-09-06 | 2013-10-01 | 주식회사 웰파이토 | Manufacturing method of functional Momordica charantia beverage for lowering blood glucose |
| CN115400189A (en) * | 2022-08-09 | 2022-11-29 | 广东药科大学 | Glycolipid-synergestic traditional Chinese medicine composition, extract, preparation method, application and preparation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6446151A (en) * | 1987-08-13 | 1989-02-20 | Nec Corp | Information processor |
| US4985248A (en) | 1987-06-18 | 1991-01-15 | Yaguang Liu | Pharmaceutical composition containing a safe extracts of fruits and vegetables for the treating and preventing of diabetes |
| KR0126431B1 (en) | 1994-07-21 | 1997-12-24 | 한동근 | Healthy food having effect of falling of blood sugar |
| JP2004291635A (en) * | 2003-03-13 | 2004-10-21 | Toray Ind Inc | Corrosion-resistant polypropylene film for metallization. metal laminate film and battery material using the same |
| KR20050014481A (en) * | 2003-07-31 | 2005-02-07 | 서상술 | Zenfood, Cooked 8 kinds of Grains rolled in dried laver |
-
2007
- 2007-10-09 KR KR1020070101381A patent/KR100831621B1/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985248A (en) | 1987-06-18 | 1991-01-15 | Yaguang Liu | Pharmaceutical composition containing a safe extracts of fruits and vegetables for the treating and preventing of diabetes |
| JPS6446151A (en) * | 1987-08-13 | 1989-02-20 | Nec Corp | Information processor |
| KR0126431B1 (en) | 1994-07-21 | 1997-12-24 | 한동근 | Healthy food having effect of falling of blood sugar |
| JP2004291635A (en) * | 2003-03-13 | 2004-10-21 | Toray Ind Inc | Corrosion-resistant polypropylene film for metallization. metal laminate film and battery material using the same |
| KR20050014481A (en) * | 2003-07-31 | 2005-02-07 | 서상술 | Zenfood, Cooked 8 kinds of Grains rolled in dried laver |
Non-Patent Citations (2)
| Title |
|---|
| 쥐의 고지방식이로 유발된 병리생리학적 변화에 있어서 청간소요산의 조절효과/동의생리병리학회지(pp.1629-1635) |
| 한약재 추출물이 흰쥐의 혈장지질 및 혈당농도에 미치는 영향/한국식품영양학회지(pp.146-151) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101130635B1 (en) | 2009-07-01 | 2012-04-09 | 주두권 | The manufacturing process of momordica charantia tea |
| KR101289084B1 (en) | 2011-12-08 | 2013-07-30 | 윤병재 | The tea containing natural medicinal herbs and the manufacturing method of it |
| CN102551061A (en) * | 2012-02-10 | 2012-07-11 | 福州市鼓楼区大特生物技术有限公司 | Canarium album granule with hypolipidemic and hypoglycemic effects and preparation process of same |
| KR101312491B1 (en) | 2012-09-06 | 2013-10-01 | 주식회사 웰파이토 | Manufacturing method of functional Momordica charantia beverage for lowering blood glucose |
| CN115400189A (en) * | 2022-08-09 | 2022-11-29 | 广东药科大学 | Glycolipid-synergestic traditional Chinese medicine composition, extract, preparation method, application and preparation |
| CN115400189B (en) * | 2022-08-09 | 2023-12-29 | 济南长庚医药科技有限公司 | Glycolipid-coordinated traditional Chinese medicine composition, extract, preparation method, application and preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100645385B1 (en) | Composition for anti-obesity | |
| JP3947012B2 (en) | Diabetes treatment composition | |
| KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
| Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
| US20110027305A1 (en) | Composition Comprising an Extract of Herbal Combination Thereof for Preventing and Treating Diabetes Mellitus | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| KR100831621B1 (en) | The plant extracts composition for the blood glucose reducing action | |
| KR100947278B1 (en) | A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof | |
| CN101243883B (en) | Health food with function of reducing blood sugar and its preparation | |
| EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
| EP1807098A1 (en) | Herbal compositions for treatment of diabetes | |
| CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| KR20090126469A (en) | The herb extract composition for the blood glucose reducing action | |
| KR20100111088A (en) | Composition for preventing and treating diabetes mellitus or diabetic complications comprising extract of herbal combination | |
| KR100376030B1 (en) | crude drug for 2type diabetes | |
| KR20140032961A (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
| KR20100102366A (en) | Composition of assitant healthful food | |
| Kamala et al. | Anti–Hyperglycemic and Anti–Hyperlipidemic Potentials of Psidium guajava Fruit Extract–a Review | |
| KR101855820B1 (en) | Composition for improving hepatic function and enhancing stamina | |
| Mukundi | Antidiabetic activity and safety of aloe volkensii, Acacia nilotica, Euclea divinorum, Rhoicissus tridentata, Cynanchum viminale and Urtica dioica in mice | |
| KR100894029B1 (en) | The ginseng fiower composition, that prevention and remedy cure to sgar diabtes | |
| CN106390034A (en) | Traditional Chinese medicine compound preparation for curing 2-diabetes | |
| KR100489564B1 (en) | Plant extract from Adenophora remotiflora and composition containing the same with hypoglycemic activity | |
| US20130058995A1 (en) | Composition and method for weight reduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120516 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20130501 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20141001 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20151116 Year of fee payment: 8 |
|
| LAPS | Lapse due to unpaid annual fee |